|   Press Release

Raze Therapeutics Launches with $24 Million Series A Financing to Advance a New Class of Oncology Therapeutics Targeting Metabolic Pathways Essential to Cancer Growth and Survival

Raze Therapeutics, a biotechnology company leading the discovery and development of a new class of oncology therapeutics that target key metabolic pathways, today announced the closing of a $24 million Series A financing. Read more.

  |   Press Release

Horizon Pharma plc Announces Presentation of ACTIMMUNE(R) Phase 2 Data in Friedreich’s Ataxia

Horizon Pharma plc, a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced today the presentation of data from a Phase 2 clinical study of ACTIMMUNE® (interferon gamma-1b) treatment in children with Friedreich’s ataxia (FA). Read more.

  |   In the News

Smart-Bug Maker Synlogic Nabs $5M From Gates Foundation

Synlogic, one of the newer biotech startups to come out of Cambridge, MA, already strung together nearly $30 million when it announced its launch in July. Now it’s topping off that round with some financial support from the Bill & Melinda Gates Foundation to help tackle some of the world’s bigger health problems. Read more.

  |   From the Trenches

Should I Stay Or Should I Go? Big Pharma Execs Taking The Biotech Plunge

That’s the dilemma facing drug hunters as leadership roles in biotech become more and more attractive. You may have noticed that more and more seasoned pharma executives are making the move from big pharma or big biotech to lead small biotech companies. Read more.

  |   In the News

Atlas to split life sciences, tech businesses

Cambridge-based venture capital firm Atlas Venture will split, with its life sciences and technology franchises becoming separate companies. Read more.